leadf
logo-loader
viewC4X Discovery Holdings PLC

C4X Discovery on hunt for next partnership deal

Snapshot

  • Chief executive Clive Dix appointed as a member and deputy chair of the steering board of the UK Vaccine Taskforce
  • Has a software-based rapid discovery platform 
  • Deal with Indivior worth £227mln in milestone payments
researcher

Quick facts: C4X Discovery Holdings PLC

Price: 19 GBX

AIM:C4XD
Market: AIM
Market Cap: £22.65 m
Follow

What C4X does

C4X Discovery Holdings plc’s (LON:C4XD) stated aim is to become the world’s most productive drug discovery engine.

To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.

It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.

This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.

Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.

It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7mln (US$10mln) and milestones of £227mln (US$294mln).

It is working on potential treatments for Parkinson’s, Alzheimer’s and inflammatory bowel disorders and it has numerous collaboration deals.

Below is the company’s drug pipeline

 

How it is doing

FTSE 250-listed drug group Indivior has taken C4X’s treatment for opioid use disorder into the clinic as part of a deal worth US$294mln. Phase I and II studies will receive financial backing from the National Institutes of Health in the US.

C4X also began a new partnership with the GEN-COVID Consortium in Italy to deploy C4X’s Taxonomy3 platform technology to examine genetic data from COVID-19 patients to identify genes specifically associated with severe types of the disease.

A phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year.

Meanwhile, its most advanced in-house programmes, NRF-2 and IL-17, continue to move forward: one of C4X’s lead NRF-2 molecules, C4X_6746, has shown significant efficacy in a pre-clinical model of inflammatory bowel disease (IBD)

 

What the boss says: Clive Dix, chief executive

“The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis."

“This is a new area for C4XD and we are excited to be working on such an important project," he commented on the project with GEN-COVID Consortium.

 

Video

 

Inflexion points

  • Clinical trial for the Orexin-1 programme with Indivior
  • A partner for the NRF-2 activator programme with the company seeing commercial interest
  • Partnership with the GEN-COVID Consortium for COVID-19 patients

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

4 weeks ago

3 min read